OakChart

Allogene Therapeutics Inc

ALLOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:10 PM ET

0.8922-0.0397 (-4.26%)
2026-11-11 18:10 CET
Market cap
322.87 USD m
Revenue, TTM
4.64 USD m
Net income, TTM
-174.46 USD m
Free cash flow, TTM
-108.81 USD m
EPS diluted, TTM
-0.62
P/E
-
Compare

Price

ALLO against its 20, 50 and 200-day averages
2050200beatearnings
1.001.502.0013.0M25.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALLOclose 0.8920-day 1.1850-day 1.46200-day 1.960.89

80.0% under the 52-week high of 4.46 on 13 Apr 2026. 52-week low 0.88 on 11 Nov 2026. Last 15 sessions, 56.8% high to low

Profile

ALLO
52-week range, 0% of the way up
0.894.46

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

IndexRUT
Employees152
IPOOct 11, 2018
Beta0.81
ATR, 14d0.10
Rel volume1.89
Short float19.83%
Insider own25.37%
Inst own71.73%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap309.12M
Enterprise Value93.10M
Income-174.46M
Sales4.64M
Book/sh1.13
Cash/sh0.85
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees152
IPOOct 11, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S66.62
P/B0.79
P/C1.06
P/FCF-
EV/EBITDA-
EV/Sales20.06
Quick Ratio7.79
Current Ratio7.79
Debt/Eq0.20
LT Debt/Eq0.17
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.62
EPS next Y-0.64
EPS next Q-0.16
EPS this Y30.59%
EPS next Y-6.43%
EPS next 5Y12.94%
EPS past 3/5Y28.61% 16.08%
Sales past 3/5Y- -
EPS Y/Y TTM36.37%
Sales Y/Y TTM-100.00%
EPS Q/Q21.94%
Sales Q/Q-
EarningsNov 05 AMC
EPS/Sales Surpr.-2.32% -100.00%

Ownership

Insider Own25.37%
Insider Trans-0.08%
Inst Own71.73%
Inst Trans26.90%
ROA-36.69%
ROE-49.29%
ROIC-37.88%
Gross Margin-140.45%
Oper. Margin-4099.33%
Profit Margin-3759.98%
SMA20-24.69%
SMA50-38.79%
SMA200-54.42%
Trades-

Technical

Shs Outstand346.28M
Shs Float258.56M
Short Float19.83%
Short Ratio7.30
Short Interest51.29M
52W High4.46 -80.00%
52W Low0.89 0.24%
Volatility12.52% 8.62%
ATR (14)0.10
RSI (14)24.34
Beta0.81
Rel Volume1.89
Avg Volume7.03M
Volume5,826,670

Performance

Perf Week-25.03%
Perf Month-30.84%
Perf Quarter-54.94%
Perf Half Y-61.71%
Perf YTD-34.88%
Perf Year-28.05%
Perf 3Y-64.31%
Perf 5Y-95.36%
Perf 10Y-
Recom1.27
Target Price8.75
Prev Close0.93
Price0.89
Change %-4.26%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Apr 16, 2026UpgradeJJP MorganUnderweight → Neutral
Apr 10, 2026ResumedJJefferiesBuy$6+572.5%
Jan 09, 2026UpgradeCCitizens JMPMkt Perform → Mkt Outperform$5+460.4%
Oct 10, 2025DowngradeJJP MorganNeutral → Underweight
May 14, 2025DowngradeCCitizens JMPMkt Outperform → Mkt Perform
Mar 14, 2025UpgradeCCitizens JMPMkt Perform → Mkt Outperform$5+460.4%
Aug 08, 2024ResumedOOppenheimerOutperform$13 → $11+1,132.9%
May 31, 2024InitiatedPPiper SandlerOverweight$11+1,132.9%
Jan 05, 2024DowngradeJJMP SecuritiesMkt Outperform → Mkt Perform
Jan 05, 2024DowngradeGGuggenheimBuy → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
CRBUCaribou Biosciences Inc41.04M
CLLSCellectis ADR110.66M
FATEFate Therapeutics Inc204.98M
SANASana Biotechnology Inc701.17M
NKTXNkarta Inc98.59M
IPSCCentury Therapeutics Inc309.04M
ACETAdicet Bio Inc28.47M
AUTLAutolus Therapeutics plc ADR334.03M
LEGNLegend Biotech Corp ADR3.67B
GILDGilead Sciences Inc209.74B

Insider trading

latest 14 of 32
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Parker Geoffrey M.CHIEF FINANCIAL OFFICEROct 21 '26Sale1.3436,34248,6981,045,877Oct 23 04:48 PM
Parker Geoffrey M.OfficerOct 21 '26Proposed Sale1.3436,34248,698Oct 21 07:48 PM
Douglas Earl MartinSVP, General CounselAug 21 '26Sale2.1229,69762,958488,267Aug 25 04:43 PM
Douglas Earl MartinOfficerAug 21 '26Proposed Sale2.1229,69762,958Aug 21 07:26 PM
Kazam Joshua ADirectorJun 18 '26Option Exercise0.0047,7000398,463Jun 23 04:35 PM
Yoshiyama AnnieSVP, FinanceApr 21 '26Sale2.319,58622,144124,517Apr 23 04:16 PM
Yoshiyama AnnieOfficerApr 21 '26Proposed Sale2.319,58622,103Apr 21 08:22 PM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 31 '26Sale2.502,8677,168195,338Apr 02 04:47 PM
Beneski Benjamin MachinasOfficerApr 01 '26Proposed Sale2.502,8677,168Apr 01 07:13 PM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 16 '26Sale2.474,83511,942198,205Mar 18 04:06 PM
Chang David DPresident and CEOMar 16 '26Sale2.4747,763117,9755,150,599Mar 18 04:05 PM
Beneski Benjamin MachinasOfficerMar 16 '26Proposed Sale2.474,83511,928Mar 16 08:20 PM
Chang David DOfficerMar 16 '26Proposed Sale2.4747,763117,827Mar 16 08:05 PM
Beneski Benjamin MachinasSVP, Chief Technical OfficerMar 02 '26Sale2.607,13218,543203,040Mar 04 05:42 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 206
  • Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease (GlobeNewswire)
  • Allogene Misses On A Wider Loss As ALPHA3 Enrollment Accelerates But Interim-Data Expectations Cool (Earnings Whispers) -8.40%
  • Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update (GlobeNewswire)
  • Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting (GlobeNewswire)
  • Loading…
  • Allogene's 39% Slide Puts Cash Runway And Alpha-3 Execution Under The Microscope (Earnings Whispers)
  • Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data (GlobeNewswire)
  • Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
  • CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot (Stocktwits)
  • Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive)
  • Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker (GlobeNewswire)
  • Allogene Therapeutics Announces Participation in September Investor Conference (GlobeNewswire)
  • Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... (GuruFocus.com)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.150-0.147-0.1500.000.0012
2026Q22026-08-12-0.130-0.171-0.1304.660.0012
2026Q12026-05-13-0.180-0.190-0.1770.000.0014
2025Q42026-03-12-0.170-0.226-0.1720.000.0014
2025Q32025-11-06-0.190-0.218-0.1860.000.0013
2025Q22025-08-13-0.230-0.268-0.2330.000.0014
2025Q12025-05-13-0.280-0.291-0.2770.000.0012
2024Q42025-03-13-0.280-0.327-0.2850.000.0117
2024Q32024-11-07-0.320-0.333-0.3170.000.0117
2024Q22024-08-07-0.350-0.350-0.3490.002.0117
2024Q12024-05-13-0.380-0.410-0.3840.020.0115
2023Q42024-03-14-0.510-0.451-0.5100.020.0218
2023Q32023-11-02-0.370-0.520-0.3660.040.0117
2023Q22023-08-02-0.530-0.589-0.5310.040.0119
2023Q12023-05-03-0.680-0.617-0.6830.050.0118
2022Q42023-02-28-0.660-0.700-0.6580.050.0819

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.830-1.894-1.8270.000.00
2020FY-2.080-2.122-2.0790.000.00
2021FY-1.890-1.964-1.34038.3638.32
2022FY-2.320-2.368-2.3780.240.18
2023FY-2.090-2.009-2.0850.100.13
2024FY-1.320-1.333-1.3220.020.02
2025FY-0.870-0.927-0.8700.000.00
2026FY--0.604--4.67
2027FY--0.643--12.92
2028FY--0.574--79.32
2029FY--0.035--350.48
2030FY-0.703--667.78

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-068000.000.000.02
2026Q4S2026-08-228000.000.000.02
2026Q4S2026-08-139000.000.000.02
2026Q4S2026-07-248000.000.000.02
2026Q4S2026-06-249000.000.000.02
2026Q4S2026-05-149100.000.000.02
2026Q4S2026-04-139100.000.000.02
2026Q4S2026-04-108100.000.000.02
2026Q4S2026-04-088010.000.000.00
2026Q4S2026-03-137010.000.000.00
2026Q4S2025-12-295000.000.000.02
2026Q4S2025-11-224000.010.000.02
2026Q4S2025-11-115000.000.000.02
2026Q4S2025-11-105000.000.000.02

Estimate history

EPS, annual0-7.306-1.827-2.079-1.34-2.378-2.085-1.322-0.865-0.6243
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.317-0.285-0.277-0.233-0.186-0.172-0.177-0.13-0.146
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000114.0890.1560.0950.02204.64
Period201720182019202020212022202320242025TTM
Sales, quarterly00000004.640
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual117.927121.483124.267140.474142.623144.438167.134212.211229.414346.28
Period201720182019202020212022202320242025MRQ
Shares, quarterly209.5212.211218.598220.134223.164229.414244.816345.345346.28
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.640.000.020.100.16114.090.000.000.00
Cost of Goods Sold Incl. D&A11.1612.3613.6414.2014.2910.4511.545.031.50
Gross Profit-6.52-12.36-13.62-14.10-14.14103.64-11.54-5.03-1.50
Selling, General and Administrative Excl. Other183.69194.57243.87300.39321.40283.83246.70196.9881.91
Research and Development122.13137.79178.66228.72242.09209.72185.40139.5142.42
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-190.21-206.93-257.48-314.49-335.54-180.19-258.24-202.01-83.41
Interest Expense1.331.070.180.000.000.000.000.003.36
Unusual Expense0.002.3815.7213.240.000.000.000.00130.65
Net Income Before Taxes-174.46-190.89-257.15-327.26-340.41-182.05-250.22-184.93-211.62
Income Taxes0.000.000.440.000.000.000.00-0.33-0.12
Consolidated Net Income-174.46-190.89-257.59-327.26-340.41-182.05-250.22-184.59-211.50
Net Income From Continuing Operations-174.46-190.89-257.59-327.26-340.41-182.05-250.22-184.59-211.50
Net Income-174.46-190.89-257.59-327.26-340.41-182.05-250.22-184.59-211.50
EPS (Recurring)-0.50-0.86-1.27-2.03-2.38-1.34-2.08-1.83-4.15
EPS (Basic, Before Extraordinaries)-0.62-0.87-1.32-2.09-2.38-1.34-2.08-1.83-7.31
EPS (Diluted)-0.62-0.87-1.32-2.09-2.38-1.34-2.08-1.83-7.31
EBITDA-179.05-194.57-243.84-300.29-321.24-169.74-246.70-196.98-81.91
Non-Operating Income (Expense)17.0819.5016.230.47-4.88-1.868.0217.085.79
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense35.8637.6440.8865.9583.6080.8065.2633.6314.67
Price To Sales Ratio119.34-18,861.325,302.645,771.7717.76---
Gross Margin-140.45--61,895.45-14,846.32-9,063.4690.84---
Operating Margin-4,099.33---331,044.21-215,087.18-157.94---
Net Margin-3,759.98---344,489.47-218,214.10-159.57---
Shares Outstanding346.28229.41212.21167.13144.44142.62140.47124.27121.48
Market Capitalization322.87322.87446.60540.17907.082,126.343,540.673,167.013,271.54

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.004.640.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A2.592.652.873.063.103.113.103.23
Gross Profit-2.592.00-2.87-3.06-3.10-3.11-3.10-3.23
Selling, General and Administrative Excl. Other52.2148.9143.2239.3541.8051.3362.0957.26
Research and Development39.3528.0829.1325.5728.0737.0547.1041.74
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-54.79-46.92-46.09-42.40-44.90-54.44-65.19-60.49
Interest Expense0.380.340.300.310.340.270.150.08
Unusual Expense0.000.000.000.000.002.380.000.00
Net Income Before Taxes-50.37-42.68-42.61-38.81-41.40-50.94-59.73-59.50
Income Taxes0.000.000.000.000.000.000.000.44
Consolidated Net Income-50.37-42.68-42.61-38.81-41.40-50.94-59.73-59.94
Net Income From Continuing Operations-50.37-42.68-42.61-38.81-41.40-50.94-59.73-59.94
Net Income-50.37-42.68-42.61-38.81-41.40-50.94-59.73-59.94
EPS (Recurring)-0.15-0.13-0.18-0.17-0.19-0.23-0.28-0.28
EPS (Basic, Before Extraordinaries)-0.15-0.13-0.18-0.17-0.19-0.23-0.28-0.28
EPS (Diluted)-0.15-0.13-0.18-0.17-0.19-0.23-0.28-0.28
EBITDA-52.21-44.27-43.22-39.35-41.80-51.33-62.09-57.26
Non-Operating Income (Expense)4.804.593.793.913.856.145.611.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.0312.448.278.138.658.6912.181.98
Price To Sales Ratio119.34147.45-----20,387.23
Gross Margin-43.00------
Operating Margin--1,011.21------
Net Margin--919.76------
Shares Outstanding346.28345.35244.82229.41223.16220.13218.60212.21
Market Capitalization322.87717.92594.82307.88275.13247.17317.21446.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments250.21292.48448.70517.32457.30827.91530.53459.380.00
Short Term Receivables1.501.901.703.306.002.802.403.110.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets6.049.018.728.208.0214.4211.645.490.00
Total Current Assets257.75303.39459.12528.82471.32845.13544.58467.980.00
Net Property, Plant & Equipment112.73131.26163.18196.43181.02160.13100.9441.610.00
Total Investments and Advances18.3490.9713.9486.76392.67217.4067.51261.970.00
Long-Term Note Receivable-------1.300.01
Intangible Assets-----0.000.150.750.00
Other Assets27.0923.106.609.565.825.174.620.240.00
Total Assets415.90548.71642.84821.581,050.831,227.83717.80773.860.01
Short Term Debt Incl. Current Port. of LT Debt8.217.516.786.003.202.970.000.000.00
Accounts Payable4.275.395.9013.8910.2610.399.2512.340.00
Other Current Liabilities20.0422.6224.4133.8434.4580.9623.8317.120.00
Total Current Liabilities32.5135.5237.0853.7347.9194.3233.0829.460.00
Long Term Debt75.0583.2588.3595.1269.9350.8151.3534.460.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities15.807.765.185.857.793.084.356.780.00
Total Liabilities123.36126.53130.60154.70125.63148.2188.7870.690.00
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity292.54422.18512.23666.88925.201,079.62629.02703.160.00
Total Shareholders Equity292.54422.18512.23666.88925.201,079.62629.02703.160.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity292.54422.18512.23666.88925.201,079.62629.02703.160.00
Total Liabilities & Stockholders Equity415.90548.71642.84821.581,050.831,227.83717.80773.860.01
Book Value Per Share1.281.993.064.626.497.695.065.793E-05
Tangible Book Value Per Share1.281.993.064.626.497.695.065.780.00
Full-Time Employees15222923336136126520612278
Price to Book Ratio0.820.960.931.222.323.285.134.65-18.68
Return on Assets-39.58-43.24-44.70-36.60-15.98-25.72-24.75-54.66-
Return on Equity-53.42-55.13-55.51-43.00-18.16-29.29-27.71-60.16-
Return on Invested Capital-51.93-50.96-54.49-44.67-18.29-22.14-27.13-28.67-66.67
Quick Ratio7.938.5412.389.849.848.9616.4615.890.00
Current Ratio7.938.5412.389.849.848.9616.4615.890.00

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-174.46-190.89-257.59-327.26-340.41-182.05-250.22-184.59-211.50
Depreciation11.1612.3613.6414.2014.2910.4511.545.031.50
Other Funds (Non Cash)30.7940.1668.4590.64101.7018.7369.6749.09153.26
Funds from Operations-132.51-138.37-175.50-222.43-224.42-152.86-169.01-130.47-56.75
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital23.89-10.88-24.80-15.303.90-31.9553.92-6.8812.10
Cash from Operating Activities-108.63-149.25-200.30-237.73-220.52-184.81-115.09-137.35-44.65
Capital Expenditures-0.18-0.39-0.69-1.52-5.19-21.45-65.96-50.79-5.33
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-117.2395.9476.38164.81111.35185.10-439.17214.88-627.47
Purchase of Investments-359.85-138.26-361.48-438.63-248.11-543.29-1,037.59-257.70-649.31
Sale Or Maturity of Investments242.62234.20437.86603.43359.46728.39598.43472.5821.84
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-117.4295.5675.69163.29106.16163.66-505.12164.08-632.80
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock217.5023.25114.3995.692.9511.96633.5958.96654.34
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock217.5023.25114.3995.692.9511.96633.5958.96654.34
Proceedsfrom Stock Options216.4022.35112.0591.110.000.00621.9354.22642.97
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00116.84
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.006.912.280.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities217.5030.16116.6795.692.9511.96633.5958.96771.18
Net Change in Cash-8.54-23.53-7.9421.25-111.41-9.1913.3885.6993.73
Free Cash Flow-108.81-149.63-200.99-239.25-225.71-206.26-181.05-188.14-49.98
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments292.96332.60266.89250.21252.19273.12
Short Term Receivables2.202.201.301.502.101.70
Inventories0.000.000.000.000.000.00
Other Current Assets4.675.205.116.046.427.83
Total Current Assets299.83340.00273.29257.75260.72282.65
Net Property, Plant & Equipment101.46105.12108.84112.73116.83120.82
Total Investments and Advances106.21101.2810.2918.3435.2439.80
Other Assets3.823.693.5327.0926.9827.31
Total Assets511.32550.09395.96415.90439.77470.59
Short Term Debt Incl. Current Port. of LT Debt8.908.668.428.218.017.76
Accounts Payable8.785.964.934.273.704.85
Other Current Liabilities20.8317.1114.9820.0420.1319.07
Total Current Liabilities38.5031.7328.3332.5131.8331.68
Long Term Debt68.0470.3572.6375.0577.1379.24
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities12.2311.8416.1215.8015.4715.12
Total Liabilities118.77113.92117.08123.36124.44126.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity392.55436.18278.88292.54315.33344.56
Total Shareholders Equity392.55436.18278.88292.54315.33344.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity392.55436.18278.88292.54315.33344.56
Total Liabilities & Stockholders Equity511.32550.09395.96415.90439.77470.59
Book Value Per Share1.131.261.141.281.411.57
Tangible Book Value Per Share1.131.261.141.281.411.57
Full-Time Employees---152--
Price to Book Ratio0.821.831.910.970.790.64
Return on Assets-36.69-32.43-38.45-39.58-41.21-42.40
Return on Equity-49.29-42.39-52.32-53.42-54.43-55.12
Return on Invested Capital-10.94-8.43-12.12-10.56-10.55-12.02
Quick Ratio7.7910.729.657.938.198.92
Current Ratio7.7910.729.657.938.198.92

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-50.37-42.68-42.61-38.81-41.40-50.94
Depreciation2.592.652.873.063.103.11
Other Funds (Non Cash)6.427.578.458.368.7611.04
Funds from Operations-41.37-32.47-31.28-27.40-29.54-36.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.250.4718.37-0.20-0.14-2.24
Cash from Operating Activities-36.12-32.00-12.91-27.60-29.69-39.03
Capital Expenditures-0.03-0.15-0.010.00-0.24-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments26.14-147.41-29.5833.6112.1843.88
Purchase of Investments-46.06-183.72-101.69-28.38-49.73-9.92
Sale Or Maturity of Investments72.2036.3172.1161.9961.9153.80
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities26.12-147.56-29.5933.6111.9443.84
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.65187.8721.127.863.241.51
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.65187.8721.127.863.241.51
Proceedsfrom Stock Options0.00187.8720.677.862.981.51
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.003.56
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.65187.8721.127.863.245.07
Net Change in Cash-9.368.32-21.3813.87-14.529.88
Free Cash Flow-36.14-32.15-12.92-27.60-29.93-39.07

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 22.00K
United States2024: 22.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3019.89%51.3M257.8M5.94M
2026-10-1520.71%53.4M257.8M5.67M
2026-09-3021.57%55.6M257.8M6.23M
2026-09-1524.92%59.6M239.1M7.21M
2026-08-3124.72%59.1M239.1M7.61M
2026-08-1424.67%58.9M238.9M7.94M
2026-07-3123.34%60.8M260.3M8.19M
2026-07-1522.94%59.7M260.3M8.82M
2026-06-3024.36%63.4M260.3M11.00M
2026-06-1518.45%48.0M260.3M10.10M
2026-05-2917.32%44.5M256.7M9.53M
2026-05-1516.54%42.3M255.6M9.53M
2026-04-3017.79%36.9M207.1M9.37M
2026-04-1516.51%36.4M220.4M8.92M
2026-03-3119.77%32.1M162.2M5.90M
2026-03-1315.06%24.4M162.2M5.13M
2026-02-2716.00%23.9M149.5M4.83M
2026-02-1313.35%20.0M149.5M4.24M
2026-01-3012.22%18.8M154.1M3.73M
2026-01-1511.63%18.6M160.2M2.96M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.350.650.499.6426052520.881-0.0070.000
call1.000.000.100.0529.6972,1650.000.990-0.0060.000
call1.500.000.050.053.2717880.000.233-0.0080.000
call2.000.000.050.034.3103,0760.000.198-0.0090.000
call2.500.000.050.015.0018850.000.181-0.0100.000
call5.000.000.050.036.4826000.000.147-0.0120.000
call7.500.000.050.057.44669.001.000.136-0.0130.000
put0.500.000.050.054.4344.000.00-0.116-0.0070.000
put1.000.000.150.1013.79520.000.00-0.430-0.0110.001
put1.500.450.650.573.1342432.00-0.768-0.0080.000
put2.000.701.650.8514.0182190.00-0.802-0.0090.000
put2.501.102.101.4614.75244.000.00-0.819-0.0100.000
put5.003.604.204.068.1151.003.00-0.850-0.0120.000
put7.506.007.000.0014.9310.000.00-0.861-0.0130.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-234Statement of changes in beneficial ownership of securities2026-10-21SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-30SCHEDULE 13D/ASEC
2026-09-028-KCurrent report2026-08-31SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-20EFFECTEffectiveness filing by commission orderSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-06-22424B5SEC
2026-05-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-288-KCurrent report2026-05-28SEC
2026-05-21DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100048.70K1
2026-090000
2026-080062.96K1
2026-070000
2026-060000
2026-050000
2026-040022.14K1
2026-0300155.63K4
2026-0200337.45K6
2026-010040.98K1
2025-120000
2025-11009591

Institutional holders

Manager% owned
BlackRock, Inc.8.73%
Frazier Life Sciences Management, L.P.6.50%
PFIZER INC6.38%
STATE STREET CORP5.51%
TPG GP A, LLC5.42%
Sio Capital Management, LLC3.86%
PRIMECAP MANAGEMENT CO/CA/3.80%
VANGUARD CAPITAL MANAGEMENT LLC3.52%
UBS Group AG3.10%
FMR LLC3.07%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.52%
Select Biotechnology Portfolio2.91%
VANGUARD CAPITAL OPPORTUNITY FUND2.72%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.51%
iShares Russell 2000 ETF2.00%
PRIMECAP Odyssey Aggressive Growth Fund1.01%
T. Rowe Price Health Sciences Fund, Inc.1.00%
VANGUARD EXTENDED MARKET INDEX FUND0.93%
Fidelity Small Cap Index Fund0.84%
abrdn Life Sciences Investors0.79%

OakChart. ALLO. Cached 15 minutes.